Biosimilars Market Set for Biggest Year Yet in 2023
PM360
APRIL 25, 2023
biosimilars market to date, the first of eight FDA-approved Humira (adalimumab) biosimilars launched in the United States in January after years of regulatory delays. Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry.
97 
Let's personalize your content